CTLA4 and neoplasm: Combined treatment using entinostat and 5-azacytidine, epigenetic modulatory drugs, with ICB antibodies (anti-PD1 and anti-CTLA4), led to complete tumor regression and metastatic progression in the aggressive triple-negative breast cancer (TNBC) model 4T1, with >80% survival rate 100 days after tumor implantation (54, 151).